News & Stories

See the latest news about CMT drug development and read stories from the CMT community that highlight why we must deliver treatments and cures during our lifetime.

CMT1A Research Update

Sep 2, 2019 | CMT Research Updates, Press Releases, Research News

CMT1A is caused by a duplication of the PMP22 gene leading to overexpression of the PMP22 protein and failure of the Schwann cells to produce myelin (the insulation of the nerve) well. Without proper myelination, the nerves don’t send signals quickly or strongly,...

CMT1B project is funded & ready for take off!

Aug 2, 2019 | CMT Research Updates, Research News

Paving pathways for mission critical projects CMT Research Foundation is partnering with Dr. Maurizio D’Antonio of I.R.C.C.S. Ospedale San Raffaele, in Milan, Italy to fund the lab’s research of Myelin Protein Zero (MPZ), the gene associated with CMT1B. Dr....

CMTRF Welcomes Dr. Grace Pavlath as Chief Science Officer

Jul 30, 2019 | Press Releases

CMT Research Foundation (CMTRF), a not-for-profit organization focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease, has added Grace Pavlath, Ph.D. to the team as the new Chief Scientific Officer. CMT is a progressive genetic nerve disease...

New research efforts by Neurogene, give hope to patients suffering with an ultra-rare type of CMT: CMT4J

Jul 19, 2019 | CMT Research Updates, Research News

Neurogene, a leading company developing genetic medicines for people with rare, devastating neurological diseases, announced today that it is recruiting patients for a natural history study for CMT4J. "Key data now being collected to support endpoint assessment for...

Is “Disease-In-A-Dish” in Combination with Animal Models A Faster Track to a Cure for CMT?

Jul 1, 2019 | CMT Research Updates, Research News

From time to time the leadership of CMTRF will explore the challenges of finding treatments and a cure for CMT. To the extent we are able, we will try to overcome these obstacles to accelerate successful CMT research. Treatment of diseases, especially rare diseases...

Scenes from BIO2019

Jun 11, 2019 | Press Releases

Last week Paul August and I attended the BIO International Convention, a conference with over 16,000 leaders from the biotech and pharmaceutical industry. We met a number of companies interested in advancing drug development for CMT. There are four primary factors...

Partnerships and Priorities: The Pathway to CMT Results

May 31, 2019 | CMT Research Updates, Press Releases, Research News

From time to time the CMT Research Foundation will examine the impediments to finding a cure for CMT. As the Chairman of a nonprofit foundation whose ONLY mission is to fund research that will lead to a cure for Charcot-Marie-Tooth disease (CMT), I am often...

New Evidence for Gene Replacement in a Mouse Model of Charcot-Marie-Tooth Disease

May 24, 2019 | CMT Research Updates, Research News

In an article published yesterday in Neurology Today, Dr. Kleopa demonstrated that gene replacement could be a viable treatment for recessive forms of CMT. CMT type 4C is a demyelinating disease, and this treatment both decreased the number of unmyelinated fibers and...

The Inherited Neuropathy Consortium (INC) welcomes the CMT Research Foundation as a partner in their Patient Advocacy Groups

Jan 9, 2019 | CMT Research Updates, Press Releases

Today the Inherited Neuropathy Consortium (INC) named the CMT Research Foundation as a partner in their Patient Advocacy Groups. This gives the CMT Research Foundation access to INC resources, researchers and its clinical infrastructure through 21 CMT Centers of...

CMTRF Inks Milestone-Driven Partnership with AcuraStem to Repurpose Established Drugs for the Treatment of CMT

Dec 20, 2018 | CMTRF Funded Research, Research News

Focus will be on expansion of AcuraStem’s patient-based discovery platform, iNeuroRx™, to leverage patient neurons and advanced informatics technology to identify promising drugs ATLANTA (December 20, 2018) The newly launched CMT Research Foundation (CMTRF), a...